Psychointegrators: Multidisciplinary Perspectives on the Therapeutic Effects of Hallucinogens

Complementary Health Practice Review

Volumn 6, Issue 3, 2001, Pages 219-237

  Winkelman, Michael ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84993734279     PISSN: 15332101     EISSN: None     Source Type: Journal    
DOI: 10.1177/153321010100600304     Document Type: Article

References (103)

1. Aberle, D. (1966). The Peyote religion among the Navaho. Chicago: Aldine.
2. Abramson, H. (Ed.). (1967). The use of LSD in psychotherapy and alcoholism. Indianapolis, IN: Bobbs-Merrill.
3. Aghajanian, G. (1981). The modulatory role of serotonin at multiple receptors in brain. In B. Jacobs & A. Gelperin (Eds.), Serotonin neurotransmission and behavior. Cambridge, MA: MIT Press.
4. Aghajanian, G. (1982). Neurophysiologic properties of psychotomimetics. In F. Hoffmeister and G. Stille (Eds.), Psychotropic agents III (pp. 89-109). New York: Springer Verlag.
5. Aghajanian, G. (1984). LSD and serotonergic dorsal raphe neurons: Intracellular studies in vivo and in vitro. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral and clinical perspectives (pp. 137-141). New York: Raven Press.
6. Aghajanian, G. (1994). Serotonin and the action of LSD in the brain. Psychiatric Annals, 2463, 137-141.
7. Alper, K., Lotsof, H., Frenken, G., Luciano, D., & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions, 8(3), 234-242.
8. Andritzky, W. (1989). Sociopsychotherapeutic functions of ayahuasca healing in Amazonia. Journal of Psychoactive Drugs, 21(1), 77-89.
9. Beck, J. (2000). MDMA in the USA: An epidemiological overview. In C. Ratsh & J. Baker (Eds.), Yearbook for Ethnomedicine and the Study of Consciousness, 6/7, 127-136.
10. Bliss, K. (1988). LSD and psychotherapy. Contemporary Drug Problems, 519-563.
11. Bravo, G. & Grob, C. (1989). Shamans, sacraments and psychiatrists. Journal of Psychoactive Drugs, 21(1), 123-128.
12. Burgess, C., O'Donohoe, A. & Gill, M. (2000). Agony and ecstasy: A review of MDMA effects and toxicity. European Psychiatry, 15(5), 287-94.
13. Calabrese, J. (1997). Spiritual healing and human development in the Native American Church: Toward a cultural psychiatry of peyote. Psychoanalytic Review, 84(2), 237-255.
14. Callaway, J. & Grob, C. (1998). Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. Journal of Psychoactive Drugs, 30(4), 367-369.
15. Carlsson, A., Waters, N. & Carlsson, M. (1999). Neurotransmitter interactions in schizophrenia-therapeutic implications. European Archives of Psychiatry, 249(4), 37-43.
16. Cohen, S. (1971). Theories on the effects of psychomimetics. In L. Madow & L. Snow (Eds.), The psychodynamic implications of physiological studies of psychomimetic drugs (pp. 3-10). Springfield, IL: Charles Thomas.
17. Davis, W. (1985). The serpent and the rainbow. New York: Simon & Schuster.
18. Delgado, P. & Moreno, F. (1998). Hallucinogens, serotonin and obsessive-compulsive disorder. Journal of Psychoactive Drugs, 30(4), 359-366.
19. Dobkin de Rios, M. (1984). Hallucinogens: Cross-cultural perspectives. Albuquerque, NM: University of New Mexico.
20. Dobkin de Rios, M. & Smith, D. (1977). Drug use and abuse in cross-cultural perspective. Human Organization, 36(1), 14-21.
21. Fink, M. (1978). Psychoactive drugs and the waking EEG 1966-1976. In M. Lipton, A. Dimascio, & K. Killam (Eds.), Psychopharmacology (pp. 691-698). New York: Raven Press.
22. Fischbach, G. (1992, September). Mind and brain. Scientific American, Special Issue, Mind and Brain, 48-57.
23. Freedman, D. (1984). LSD: The bridge from human to animal. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral, and clinical perspectives (pp. 203-226). New York: Raven Press.
24. Furst, P. (Ed.). (1972). Flesh of the gods. New York: Praeger.
25. Furst, P. (Ed.). (1976). Hallucinogens and culture. San Francisco, CA: Chandler and Sharp.
26. Glennon, R. (1990). Serotonin receptors: Clinical implications. Neuroscience and Biobehavioral Reviews, 14, 35-47.
27. Gold, M. (Ed.). (1994a). The new psychedelic subculture. Psychiatric Annals, 24(3).
28. Gold, M. (1994b). The epidemiology, attitudes and pharmacology of LSD use in the 1990. Psychiatric Annals, 24(3), 124-126.
29. Greer, G., & Tolbert, R. (1998). A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs, 30(4), 371-379.
30. Grob, C., & Dobkin de Rios, M. (1992). Adolescent drug use in cross-cultural perspective. Journal of Drug Issues, 22(1), 121-138.
31. Grof, S. (1975). Realms of the unconscious: Observations from LSD Research. New York: Viking Press.
32. Grof, S. (1980). LSD psychotherapy. Pomona, CA: Hunter House.
33. Grof, S. (1992) The holotropic mind. San Francisco: Harper Collins.
34. Halpern, J. & Pope, H. (1999). Do hallucinogens cause residual neuropsychological toxicity? Drug & Alcohol Dependence, 53(3), 247-256.
35. Hamon M. (1984). Common neurochemical correlates to the action of hallucinogens. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral and clinical perspectives (pp. 143-170). New York: Raven Press.
36. Harner, M. (Ed.). (1973). Hallucinogens and shamanism. New York: Oxford University Press.
37. Heggenhougen, C. (1997). Reaching new highs: Alternative therapies for drug addicts. Northvale, NJ: Jason Aronson.
38. Hoffmeister, F. & Stille, G. (Eds.). (1982). Psychotropic agents III. New York: Springer Verlag.
39. Hollister, L. (1984). Effects of hallucinogens in humans. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral and clinical perspectives (pp. 203-226). New York: Raven Press.
40. Jacobs, B. (1984a). (Ed.). Hallucinogens: Neurochemical, behavioral, and clinical perspectives. New York: Raven Press.
41. Jacobs, B. (1984b). Postsynaptic serotonergic action of hallucinogens. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral, and clinical perspectives, (pp. 183-202). New York: Raven Press.
42. Jacobs, B., & Gelperin, A. (Eds.). (1981). Serotonin neurotransmission and behavior. Cambridge, MA: MIT Press.
43. Jacobs, B. & Trulson, M. (1981). The role of serotonin in the action of hallucinogenic drugs. In B. Jacobs & A. Gelperin (Eds.), Serotonin neurotransmission and behavior. Cambridge, MA: MIT Press.
44. Jacobs, D. (1996). The use of Datura in rites of transition. In M. Winkelman & W. Andritsky (Eds.), Sacred plants, consciousness and healing (pp. 341-351). Yearbook of cross-cultural medicine and psychotherapy, 5. Berlin: VWB.
45. Jilek, W. (1994). Traditional healing and the prevention and treatment of alcohol and drug abuse. Transcultural Psychiatric Research Review, 31, 219-258.
46. Kruk, Z. & Pycock, C. (1991). Neurotransmitters and drugs. London: Chapman and Hall.
47. Kurland, A. (1985). LSD in the supportive care of the terminally ill cancer patient. Journal of Psychoactive Drugs, 17 (4), 279-290.
48. La Barre, W. (1970). Old and New World narcotics: A statistical question. Economic Botany, 24, 368-373.
49. La Barre, W. (1972). Hallucinogens and the shamanic origins of religion. In P. Furst (Ed.), Flesh of the gods (pp. 261-278). New York: Praeger.
50. Laughlin, C., McManus, J. & d'Aquili, E. (1992). Brain, symbol and experience toward a neurophenomenology of consciousness. New York: Columbia University Press.
51. Leary, T. (1997). Psychedelic prayers and other meditations. Berkeley, CA: Ronin Publishing Co.
52. Lukoff, D., Zanger, R. & Lu, F. (1990). Transpersonal psychology research review: Psychoactive substances and transpersonal states. Journal of Transpersonal Psychology, 22(2), 107-147.
53. Mabit, J., Giove R. Vega J. (1996). Takiwasi: The use of Amazonian shamanism to rehabilitate drug addicts. In M. Winkelman W. Andritzky (Eds.), Sacred plants, consciousness and healing. Yearbook of Cross-Cultural Medicine and Psychotherapy, 5 (pp. 257-85). Berlin: VWB.
54. MacLean, P. (1990). The triune brain in evolution. New York: Plenum.
55. Mandell, A. (1980). Toward a psychobiology of transcendence: God in the brain. In D. Davidson and R. Davidson (Eds.), The psychobiology of consciousness (pp. 379-464). New York: Plenum.
56. Mandell, A. (1985). Interhemispheric fusion. Journal of Psychoactive Drugs, 17(4), 257-266.
57. Mangini, M. (1998). Treatment of alcoholism using psychedelic drugs: A review of the program of research. Journal of Psychoactive Drugs, 30(4), 381-418.
58. Mathias, R. (1993). NIDA research takes a new look at LSD and other hallucinogens. NIDA Notes, 8(1), 6-11.
59. McKim, W. (1991). Drugs and behavior: An introduction to behavioral pharmacology. Englewood Cliffs, NJ: Prentice-Hall.
60. Metzner, R. (1998). Hallucinogenic drugs and plants in psychotherapy and shamanism. Journal of Psychoactive Drugs, 30 (4), 333-431.
61. Miller, N. & Gold, M. (1993). LSD and ecstasy: Pharmacology, phenomenology and treatment. Psychiatric Annals, 24(3), 131-134.
62. Naranjo, C. (1996). The interpretation of psychedelic experience in light of the psychology of meditation. In M. Winkelman & W. Andritsky (Eds.), Sacred plants, consciousness and healing (pp. 75-90). Yearbook of Cross-Cultural Medicine and Psychotherapy, 5. Berlin: VWB.
63. Ott, J. (1993). Pharmacotheon. Kennewick, WA: Natural Products.
64. Ott, J. (1994). Ayahuasca analogues. Kennewick, WA: Natural Products.
65. Parent, A. (1981). The anatomy of serotonin-containing neurons across the phylogeny. In B. Jacobs & A. Gelperin (Eds.), Serotonin neurotransmission and behavior. Cambridge, MA: MIT Press.
66. Parrott, A., Sisk, E., & Turner, J. (2000). Psychobiological problems in heavy “ecstasy” (MDMA) polydrug users. Drug & Alcohol Dependence, 60(1), 105-110.
67. Passie, T. (1997). Psycholytic and psychedelic therapy research, 1931-1995: A complete international bibliography. Hannover, Germany: Laurentius Publishers.
68. Praag, H. (1991). The present and future of serotonergic drugs. Human Psychopharmacology, 6, 513-519.
69. Rätsch, C. (Ed.), (1989). Gateway to inner space, sacred plants, mysticism and psychotherapy. Bridgeport, Dorset: Prisim Press.
70. Ribeiro, C. (1991). Pharmacology of serotonin neuronal systems. Human Psychopharacology, 6, 37-51.
71. Riedlinger, T. & Riedlinger, J. (1994). Psychedelic and entactogenic drugs in the treatment of depression. Journal of Psychoactive Drugs, 26(1), 41-55.
72. Roberts, T. (1999). Do entheogen-induced mystical experiences boost the immune system? Psychedelics, peak experiences, and wellness. Advances in Mind-Body Medicine, 15, 139-147.
73. Roberts, T. (Ed.). (2000). Psychoactive sacraments. San Francisco: Council on Spiritual Practices.
74. Role, L., & J. Kelly. (1991). The brain stem: Cranial nerve nuclei and the monoaminergic systems. In E. Kandal, J. Schwartz & T. Jessell (Eds.), Principles of neural science, (pp. 683-699). New York: Elsevier.
75. Ryall, R. (1989). Mechanisms of drug action on the nervous system. Cambridge, UK: Cambridge University Press.
76. Sanchez-Ramos, & J., Mash, D. (1996). Pharmacotherapy of drug dependence with ibogain. In M. Winkelman & W. Andritzky (Eds.), Sacred plants, consciousness and healing. Yearbook of Cross-Cultural Medicine and Psychotherapy, 5, 353-367. Berlin: VWB.
77. Schmidt, A., & Peroutka, S. (1989). S-Hydroxytryptamine Receptor “Families.” Neuropsychopharmacology, 3, 2242-2249.
78. Schultes, R. (1972). An overview of hallucinogens in the western hemisphere. In P. Furst (Ed.), Flesh of the gods, (pp. 3-54). New York: Praeger.
79. Schultes, R., & Hofmann, A. (1979). Plants of the gods origins of hallucinogenic use. New York: McGraw Hill. (Reprinted 1992 by Healing Arts Press, Rochester, Vermont).
80. Schultes, R., & Winkelman, M. (1996). The principal American hallucinogenic plants and their bioactive and therapeutic properties. In M. Winkelman & W. Andritsky (Eds.), Sacred plants, consciousness and healing (pp. 205-239). Yearbook of Cross-Cultural Medicine and Psychotherapy, 5. Berlin: VWB.
81. Schuster, P., Lieb, R. Lamertz, C. & Wittchen, H. (1998). Is the use of ecstasy and hallucinogens increasing? Results from a community study. European Addiction Research, 4(1-2), 75-82.
82. Shannon, B. (2000). Cognitive psychology and the study of Ayahuasca, In C. Ratsch & J. Baker (Eds.), Yearbook for Ethnomedicine and the Study of Consciousness, 6/7, 77-94.
83. Shulgin, A., & Shulgin, A. (1995). Phikal. Berkeley, CA: Transform Press.
84. Siegel, R. (1984). The natural history of hallucinogens. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral and clinical perspectives (pp. 1-18). Raven Press: New York.
85. Siegel, R. (1990). Intoxication: Life in pursuit of artificial paradise. New York: Dutton.
86. Smith, D., & Seymour, R. (1994). LSD: History and toxicity. Psychiatric Annals, 24(3), 145-147.
87. Smith, H. (2000). Cleansing the doors of perception: The religious significance of enthenogenic plants and chemicals. New York: J. P. Tarcher.
88. Stafford, P. (1992). Psychedelics encyclopedia. Berkeley, CA: Ronin Press.
89. Wasson, R., Kramrisch, S., Ott, J., & Ruck, C. (1986). Persephone's quest: Ethnogens and the origins of religion. New Haven, CT: Yale University Press.
90. Wasson, R. (1980). The wondrous mushroom: Mycolatry in Mesoamerica. New York: McGraw Hill.
91. Werner M. (1993) Hallucinogens. Pediatrics in Review, 14(12), 466-472.
92. Winkelman, M. (1986a). Trance states: A theoretical model and cross-cultural analysis. Ethos, 14(2), 174-203.
93. Winkelman, M. (1986b). Magico-religious practitioner types and socioeconomic conditions. Behavior Science Research, 20, 17-46.
94. Winkelman, M. (1990). Shaman and other “magico-religious” healers: A cross-cultural study of their origins, nature, and social transformations. Ethos, 18, 308-352.
95. Winkelman, M. (1991). Physiological, social and functional aspects of drug and non-drug altered states of consciousness. In W. Andritzky (Ed.), Yearbook of cross-cultural medicine and psychotherapy, 1990 (pp. 183-198). Berlin: VWB-Verlag.
96. Winkelman, M. (1992). Shamans, priests and witches. A cross-cultural study of magico-religious practitioners (Anthropological Research Papers #44. Arizona State University.
97. Winkelman, M. (1996). Psychointegrator plants: Their roles in human culture and health. In M. Winkelman & W. Andritzky (Eds.), Sacred plants, consciousness and healing. Yearbook of cross-cultural medicine and psychotherapy, 5 (pp. 9-53). Berlin: VWB.
98. Winkelman, M. (2000). Shamanism: The neural ecology of consciousness and healing. Westport, CT: Bergin & Garvey.
99. Winkelman, M., & Andritzky, W. (Eds.). (1996). Sacred plants, consciousness and healing. Yearbook of cross-cultural medicine and psychotherapy, 5. Berlin: VWB.
100. Yensen, R. (1985). LSD and psychotherapy. Journal of Psychoactive Drugs, 17(4), 267-277.
101. Yensen, R. (1996). From shamans and mystics to scientists and psychotherapists. In M. Winkelman & W. Andritzky (Eds.), Sacred plants, consciousness and healing. Yearbook of cross-cultural medicine and psychotherapy (Vol. 5, pp. 109-128). Berlin: VWB.
102. Zanger, R. (1989). Psycholytic therapy in Europe. Newsletter: The Albert Hoffman Foundation, 1(2).
103. Zoccolillo, M., Vitaro, F., & Tremblay, R. (1999). Problem drug and alcohol use in a community sample of adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38(7), 900-907.